Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-MIRC208 SPECT/CT in HER2-Positive Cancer
NCT04591652Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Open-label, single-arm trial of 99mTc-MIRC208 in cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Standardized Uptake Value at 3 years. Status: unknown.
02
Drugs
99mTc-MIRC208
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04591652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04591652.